TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10418923
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (D x UK) - two doses
Study: 7908246
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (12 micrograms)
Study: 138664
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate containing 60 mg elemental iron twice daily
Study: 138664
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg twice daily
Study: 138664
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of iron and folic acid
Study: 24392555
Drug: Subconjunctival bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival bevacizumab (2.5 mg/0.1 ml)
Study: 24392555
Drug: Topical bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical bevacizumab (2.5%, 25 mg/ml)
Study: 24392555
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (Control Group B)
Study: 11033396
Drug: Direct argon-green
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct argon-green laser photocoagulation for CNV treatment
Study: 9183445
Drug: Classical biological
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical biological explorations
Study: 8331618
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion (0.25 mU/kg/min)
Study: 8331618
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin infusion (1.0 mU/kg/min)
Study: 8331618
Drug: Basal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal and insulin infusion periods
Study: 20880171
Drug: Lafutidine 10
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine 10 mg administered twice daily for 14 days
Study: 20880171
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for 14 days
Study: 18248495
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (standard therapy)
Study: 17176334
Drug: Higher transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher transfusion threshold (10 g per dL)
Study: 17176334
Drug: Lower transfusion
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower transfusion threshold (7 g per dL)
Study: 10854006
Drug: Lacidipine (4‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4‐6 mg od)
Study: 10854006
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (25‐50 mg od)
Study: 29678523
Drug: Adipose tissue-derived
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue-derived mesenchymal stem cell (ASC) therapy
Study: 27326859
Drug: Azithromycin-Chloroquine (AZCQ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin-Chloroquine (AZCQ; 250 mg AZ/155 mg CQ base)
Study: 27326859
Drug: Sulfadoxine-Pyrimethamine (SP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-Pyrimethamine (SP; 1,500/75 mg SP QD for 1 day)
Study: 18588481
Drug: IC51 (inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC51 (inactivated Japanese encephalitis vaccine)
Study: 11092282
Drug: Ultralente insulin
Normalized name: ultralente insulin, beef
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralente insulin therapy
Study: 8340194
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg bid for 5-14 days
Study: 8340194
Drug: Cefadroxil 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 500 mg bid for 5-14 days
Study: 8340194
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg qid for ≤ 14 days
Study: 8340194
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg qid for ≤ 14 days
Study: 21194827
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg)
Study: 18362485
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (n = 29)
Study: 12911202
Drug: Macintosh laryngoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macintosh laryngoscope (group L)
Study: 10571611
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of pantoprazole (2 x 40 mg, Group 2PCA)
Study: 10571611
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of pantoprazole (40 mg, Group 1PCA)
Study: 10571611
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (double and single dose of pantoprazole)
Study: 1925193
Drug: Fixed triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed triple combination (0.05 mg reserpine, 2.5 mg clopamide, 0.4 mg dihydroergocristine)
Study: 1925193
Drug: Fixed double
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed double combination (0.05 mg reserpine, 2.5 mg clopamide)
Study: 1925193
Drug: Fixed triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed triple combination
Study: 1925193
Drug: Fixed double
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed double combination
Study: 28027794
Drug: Intraperitoneal vancomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal vancomycin, 1g, every 5 days plus oral moxifloxacin, 400mg, every day
Study: 25863661
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant human erythropoietin (rhEpo) 3000 U/kg body weight
Study: 25863661
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant human erythropoietin (rhEpo)
Study: 21335616
Drug: PONI (modular
Approvals — FDA: no, EMA: no, PMDA: no
Description: PONI (modular protocol for on-site, nurse-administered intervention)
Study: 11293559
Drug: 100-mg sumatriptan
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg sumatriptan tablets
Study: 11293559
Drug: 50-mg sumatriptan
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg sumatriptan tablets
Study: 8083076
Drug: r‐HuEPO (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO (200 U/kg/day) and ferrous sulfate 5‐10 days prior to initiation of external beam radiation therapy
Study: 2754150
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of 4.5% saline via higher output nebulizer
Study: 31005385
Drug: Levetiracetam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (40 mg/kg over 5 min)
Study: 31005385
Drug: Phenytoin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (20 mg/kg over at least 20 min)
Study: 25811584
Drug: 50% inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% inhaled oxygen
Study: 23789452
Drug: hilifox‐750 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: hilifox‐750 (750 mg daily for 5 days)
Study: 23789452
Drug: amoxiclav (875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxiclav (875/125 mg twice daily for 10 days)
Study: 20696676
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin-docetaxel (D 75 mg/m² on day 1 and C 40 mg/m² on days 1 and 2) followed by concurrent chemoradiotherapy (66 Gy with weekly D 20 mg/m² and C 20 mg/m²)
Study: 20696676
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy with cisplatin-docetaxel (D 75 mg/m² on day 1 and C 40 mg/m² on days 1 and 2) followed by concurrent chemoradiotherapy (66 Gy with weekly D 20 mg/m² and C 20 mg/m²)
Study: 12634224
Drug: CsA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA plus MTX combination therapy
Study: 9367069
Drug: Oral retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral retinol (25,000 IU) daily for up to 5 years
Study: 3866866
Drug: Weekly mouthrinsing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly mouthrinsing with a 0.2 percent NaF solution
Study: 3866866
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (semiannual fluoride varnish treatments)
Study: 25219106
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with wheat, up-dosing phase until 100 g tolerated, followed by 6-month maintenance phase
Study: 25219106
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with wheat
Study: 22872467
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg E(2)
Study: 20968271
Drug: Quercetin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin supplementation (1 g/d for 6 weeks)
Study: 18303020
Drug: sifuvirtide (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sifuvirtide (5, 10, 20, 30, and 40 mg) by subcutaneous injection once daily
Study: 12747278
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisone daily
Study: 25382826
Drug: Prodrug (LY2140023)
Normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prodrug (LY2140023) 80 mg oral
Study: 25382826
Drug: Prodrug (LY2140023)
Normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prodrug (LY2140023) 80 mg oral and 100 μg i.v.
Study: 25382826
Drug: Active moiety
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active moiety (LY404039) 100 μg i.v.
Study: 24342198
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (HFOV, PS, iNO)
Study: 24342198
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (HFOV, iNO)
Study: 11499744
Drug: L-arginine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (15 g daily)
Study: 7528908
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment in 17 children
Study: 28258526
Drug: Medication advertisement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication advertisement
Study: 17009253
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of sCT
Study: 17009253
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of sCT
Study: 3114548
Drug: Bupranolol 100
Normalized name: bupranolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupranolol 100 mg
Study: 24029546
Drug: Oral laquinimod
Normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral laquinimod (0.6 mg)
Study: 20503023
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon plus ribavirin (800-1200 mg/d)
Study: 10882164
Drug: Tropisetron monotherapy
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron monotherapy
Study: 10882164
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone and tropisetron
Study: 10882164
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose metoclopramide plus dexamethasone
Study: 31784365
Drug: Leukocyte-rich platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte-rich platelet-rich plasma (PRP) injection
Study: 30528317
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment (2%) dressings
Study: 25510856
Drug: Clarithromycin (CYP3A4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (CYP3A4 inhibitor)
Study: 25510856
Drug: Clarithromycin +
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin + Paroxetine (CYP3A4 + CYP2D6 inhibitors)
Study: 25510856
Drug: O‐desmethylvenlafaxine <
Approvals — FDA: no, EMA: no, PMDA: no
Description: O‐desmethylvenlafaxine < 4 and venlafaxine + O‐desmethylvenlafaxine > 400 ng/ml
Study: 19147401
Drug: OSAS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSAS treatment (CPAP and MAD)
Study: 16903598
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Yueyueshu Powder, twice a day, 10 g each time for 3 menstrual cycles
Study: 9251274
Drug: ACTHIB vaccine
Normalized name: ActHIB vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTHIB vaccine given with primary immunization (age group 6 to 8 weeks) in 50 babies
Study: 9251274
Drug: ACTHIB vaccine
Normalized name: ActHIB vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTHIB vaccine
Study: 8104070
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HD-CY; 7 g/m2) alone
Study: 8104070
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HD-CY; 7 g/m2) with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; 5 micrograms/kg/day iv after HD-CY)
Study: 31971832
Drug: Interdisciplinary Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary Therapy (IT) (n = 19)
Study: 23014796
Drug: CON (rest
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (rest without treatment)
Study: 19363237
Drug: Sclerovit (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerovit (1 capsule)
Study: 19363237
Drug: Sclerovit (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerovit (2 capsules)
Study: 10965289
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and behavioral treatment
Study: 8857862
Drug: Topical 60%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 60% DMSO applied every 4 hours for 10 days after operation
Study: 1536829
Drug: Two Gabor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Gabor patches with different spatial frequencies identified in parallel when occupying the same spatial position.
Study: 1536829
Drug: Two Gabor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Gabor patches with the same spatial frequency identified in parallel even when separated by 8 degrees.
Study: 1536829
Drug: Two Gabor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Gabor patches with different spatial frequencies separated by 4 degrees or more.
Study: 6369520
Drug: Single-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose group (500 mg of tinidazole intravenously preoperatively)
Study: 6369520
Drug: 3-day group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day group (500 mg of tinidazole intravenously preoperatively + 3-day tinidazole treatment)
Study: 28525636
Drug: Movement group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement group (unimanual pattern of five sequential keystrokes)
Study: 22659072
Drug: CBT4BN (Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4BN (Internet-based cognitive-behavioral therapy)
Study: 22659072
Drug: CBTF2F (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBTF2F (traditional face-to-face cognitive-behavioral therapy)
Study: 18838638
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management plus naltrexone therapy
Study: 18838638
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management plus combined naltrexone and acamprosate therapy
Study: 11859850
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation oral contraceptive (30 microg ethinylestradiol/150 microg levonorgestrel)
Study: 11859850
Drug: Third generation
Normalized name: Third generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third generation oral contraceptive (30 microg ethinylestradiol/150 microg desogestrel)
Study: 2938985
Drug: Desogestrel-containing preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing preparations
Study: 11859850
Drug: Progestagen-only pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestagen-only pills (150 microg desogestrel)
Study: 23929692
Drug: Error Augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error Augmentation (EA) training
Study: 21817123
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with inert metal disks, same protocol as SMS
Study: 17161670
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lafutidine b.d.
Study: 15142209
Drug: SRP+500 mg
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP+500 mg of systemic tetracycline twice/day for 14 days
Study: 10700052
Drug: Verapamil 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 5 mg
Study: 17126782
Drug: Lidocaine 10
Normalized name: lidocaine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 10 mg
Study: 9575643
Drug: Milgamma tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milgamma tablets (50 mg benfothiamine and 0.25 mg cyancobalamine)
Study: 9575643
Drug: Neurobex tablets
Normalized name: lidocaine hydrochloride Topical Cream [Neuromed]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurobex tablets
Study: 8417806
Drug: rHuEPO (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (400 to 1,500 U per kg twice daily [BID] per week)
Study: 8417806
Drug: Open label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label rHuEPO administration
Study: 2847454
Drug: 10% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose infusion with phosphate buffer (10 mmol phosphate buffer/l)
Study: 2847454
Drug: 10% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose infusion without phosphate supplement
Study: 31353479
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of racemic carvedilol 25 mg (CAR)
Study: 31353479
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of racemic lercanidipine 20 mg (LER)
Study: 31353479
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of CAR plus LER
Study: 26043025
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg po daily
Study: 23602424
Drug: Gentamicin solution
Normalized name: gentamicin Injectable Solution
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin solution lavage (Group 2)
Study: 20541841
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day donepezil hydrochloride
Study: 16813139
Drug: Toothbrush T2
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toothbrush T2 (Oral B Advantage Control Grip - Oral B)
Study: 9100160
Drug: Libido (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Libido (3 g twice daily)
Study: 8468765
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (250 mg every 6 hours for 3 days) followed by oral prednisone (1 mg/kg per day for 11 days)
Study: 8512477
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (1 mg/kg per day for 14 days)
Study: 8468765
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo for 14 days
Study: 3963356
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg nalbuphine
Study: 29461920
Drug: Creating Change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creating Change (CC)
Study: 22385472
Drug: Acotiamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide (100 mg t.i.d.)
Study: 20446587
Drug: Non-aspirin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin (control group)
Study: 10235086
Drug: Trapidil 300
Normalized name: trapidil
DrugBank: Trapidil (DB09283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil 300 mg/day
Study: 12895190
Drug: Clomethiazole (68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomethiazole (68 mg kg(‐1) as a three-phase i.v. infusion over 24 h)
Study: 28825195
Drug: CIM treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIM treatments (≥4 treatments, ≤30 days apart)
Study: 28825195
Drug: CIM treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIM treatments (AIC group)